Lacosamide Upptrappningsförpackning (Endast För Ungdomar Och Barn Som Väger 50 Kg Eller Mer Samt Vux (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, which stabilises hyper‑excitable membranes and reduces repetitive neuronal firing. This action diminishes the likelihood of seizure generation without affecting the fast inactivation phase of the channels.

The dosage of lacosamide is individualised by the prescribing clinician. Typically, treatment starts with a low dose that is gradually increased according to the patient’s response and tolerability, following the prescriber’s specific instructions.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation, which may result in a different side‑effect profile and fewer drug‑interaction concerns. It is often chosen when patients need an additional mechanism of action or have not responded adequately to other agents.

Lacosamide tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally as a tablet. Swallow the tablet whole with a glass of water; it may be taken with or without food. Follow the prescriber’s instructions regarding timing and any dose‑adjustment schedule.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and the emergence of suicidal thoughts or behaviour. Patients should be monitored for these events, and any concerning symptoms should be reported promptly.

Lacosamide is contraindicated in individuals with known hypersensitivity to the drug, those with significant cardiac conduction disorders (e.g., second‑ or third‑degree AV block), and patients taking medications that may cause dangerous interactions without appropriate monitoring.